anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
ABSTRACT OF THE DISCLOSURE           Novel oligopeptides used as reagents or in the preparation of reagents in relation to gamma-carboxyglutamic acid-containing protein of bone.          Particularly, labeled oligopeptides and antibodies prepared from immunogen conjugates are disclosed for use in immu-noassays.  The oligopeptides of the invention have substan-tially the same amino acid sequence as regions of hBGP.  By having oligopeptides that immunogenically mimic regions of BGP antibodies can be obtained that are highly specific for BGP and regions of BGP.  Therefore, in conducting immu-noassays, cross reactivity is minimized and a high binding titer is provided.  Further as the oligopeptides of the invention are much smaller than the natural hBGP they can be synthesized readily.
The need for evidence-based mental health treatments i.e., 'treatment based on the best available science or research evidence', has been stressed from scientific, ethical, and economic perspectives. While empirical evidence supports both the efficacy and effectiveness of cognitive behavior therapy (CBT) for anxiety disorders, the demand for clinicians trained in these approaches far exceeds the supply. A major reason for this is the lack of trained cognitive behavior therapists. New technologies provide the opportunity to both facilitate accessibility to this specialized training by mental health professionals and to improve the quality of this training. Recent research has found that training clinicians using these new web-based technologies is highly effective, can significantly improve skills, and has significant advantages over traditional training programs. The long term goal of this project is to increase the number of available mental health professionals trained in cognitive behavior therapy for anxiety disorders by developing a set of web-based training tools enabling the widespread dissemination of this training. In Phase I the investigators developed a prototype online tutorial covering some core CBT principles and a Social Anxiety Disorder module. The investigators also tested the feasibility of live remote training through videoconferencing. In phase II investigators will expand the tutorial to include a comprehensive review of CBT principles and techniques and expand modules to include the full spectrum of anxiety and anxiety-related disorders (i.e., Obsessive Compulsive Disorder, Panic Disorder, Generalized Anxiety Disorder, Posttraumatic Stress Disorder and Social Anxiety Disorder). Investigators will also evaluate the efficacy of live remote training in improving clinical skills. A cohort of 50 clinicians from diverse educational and professional backgrounds will be recruited. Improvement in trainees' conceptual knowledge will be evaluated pre and post tutorial, and improvement in trainees' clinical skills in applying the CBT concepts will be evaluated by blind ratings of clinical adherence and competence at three time points: before on-line training, and before and after videoconference training. User satisfaction with both the on-line tutorial and the videoconference training will also be evaluated. Impact of training on post-training patient outcomes will be evaluated.
The invention provides a lentiviral vector containing an attachment incompetent fusogenic polypeptide and a heterologous targeting polypeptide. Also provided is a lentiviral packaging construct. The construct contains a nucleic acid encoding trans-acting factors sufficient for lentiviral vector generation and an attachment incompetent fusogenic polypeptide. A lentiviral packaging system having at least two nucleic acid vectors is further provided. The lentiviral packaging system consists of a first nucleic acid vector comprising a packaging construct encoding a trans-acting factor for lentiviral vector generation, and a second nucleic acid vector encoding an attachment incompetent fusogenic polypeptide, said at least two vectors together encoding trans-acting factors sufficient for lentiviral vector generation. The invention additionally provides a lentiviral gene delivery system having at least three nucleic acid vectors. The gene delivery system consists of: a first nucleic acid vector comprising a packaging construct encoding a trans-acting factor for lentiviral vector generation; a second nucleic acid vector comprising a fusogenic construct encoding an attachment incompetent fusogenic polypeptide, and a third nucleic acid vector comprising a lentiviral vector genome encoding lentiviral cis sequences sufficient for vector genome transduction, said at least three vectors together encoding trans-acting factors sufficient for lentiviral vector generation. Finally, methods of transducing a cell and methods of targeting a gene to a cell or tissue using the lentiviral vectors and systems of the invention are also provided.
Patients will receive standard of care behavior and nutritional interventions. They will receive cyproheptadine every day for a total of two months. Standard dose of 0.25 mg/kg divided BID will be used.
Post-traumatic stress disorder (PTSD) is a debilitating mental health disease related to traumatic experience, and its treatment outcomes are unsatisfactory. Accumulating research has indicated that cannabidiol (CBD) exhibits anti-PTSD effects, however, the underlying mechanism of CBD remains inadequately investigated. Although many studies pertaining to PTSD have primarily focused on aberrations in neuronal functioning, the present study aimed to elucidate the involvement and functionality of microglia/macrophages in PTSD while also investigated the modulatory effects of CBD on neuroinflammation associated with this condition. We constructed a modified single-prolonged stress (SPS) mice PTSD model and verified the PTSD-related behaviors by various behavioral tests (contextual freezing test, elevated plus maze test, tail suspension test and novel object recognition test). We observed a significant upregulation of Iba-1 and alteration of microglial/macrophage morphology within the prefrontal cortex and hippocampus, but not the amygdala, two weeks after the PTSD-related stress, suggesting a persistent neuroinflammatory phenotype in the PTSD-modeled group. CBD (10 mg/kg, i.p.) inhibited all PTSD-related behaviors and reversed the alterations in both microglial/macrophage quantity and morphology when administered prior to behavioral assessments. We further found increased pro-inflammatory factors, decreased PSD95 expression, and impaired synaptic density in the hippocampus of the modeled group, all of which were also restored by CBD treatment. CBD dramatically increased the level of anandamide, one of the endocannabinoids, and cannabinoid type 2 receptors (CB2Rs) transcripts in the hippocampus compared with PTSD-modeled group. Importantly, we discovered the expression of CB2Rs mRNA in Arg-1-positive cells in vivo and found that the behavioral effects of CBD were diminished by CB2Rs antagonist AM630 (1 mg/kg, i.p.) and both the behavioral and molecular effects of CBD were abolished in CB2Rs knockout mice. These findings suggest that CBD would alleviate PTSD-like behaviors in mice by suppressing PTSD-related neuroinflammation and upregulation and activation of CB2Rs may serve as one of the underlying mechanisms for this therapeutic effect. The present study offers innovative experimental evidence supporting the utilization of CBD in PTSD treatment from the perspective of its regulation of neuroinflammation, and paves the way for leveraging the endocannabinoid system to regulate neuroinflammation as a potential therapeutic approach for psychiatric disorders.
A composition of the present invention comprises a copolymer having silyl groups at least one reactive functional group bonded thereto. The copolymer preferably comprises, as one of constitutive monomers, Monomer (A) shown by the following Formula (I): <CHEM> wherein R1 is hydrogen atom or methyl; R2 alkylene group having 1-6 carbon atoms; and R3, R4 and R5 each is a reactive functional group which can cross-link molecules of the copolymer by hydrolyzing. Further, the copolymer preferably comprises, as a constitutive monomer, an alkyl (meth)acrylate and a siloxane-containing (meth)acrylate. The coat-forming method of the present invention comprises hydrolyzing the composition on a material to be treated to cross-link molecules of the copolymer,thereby forming a coat of the cross-linked copolymer having excellent resistance to washing. This coat can exhibit hair nature modifying effect, make-up retention improving effect, and skin-protecting effect. Also, it can impart water-repellency, unsusceptibility to fouling, suitability for sizing and crease resistance to fibers. Further, it can improve skin-cleaning effect, applicability, strippability and coat-strength of a peeling-off type cosmetic pack. <IMAGE>
Drug abuse is intentional non-therapeutic use of a drug, even once, for its rewarding psychological and physiological effects. Abuse and misuse of testosterone are seen in male and female adults and adolescents. Testosterone, often in combination with other anabolic androgenic steroids (AAS), and not obtained by prescription through a pharmacy, may be abused by athletes and bodybuilders. There have been reports of misuse by men taking higher doses of legally obtained testosterone than prescribed and continuing testosterone despite adverse events or against medical advice.

Abuse-Related Adverse Reactions 

Serious adverse reactions have been reported in individuals who abuse anabolic androgenic steroids and include cardiac arrest, myocardial infarction, hypertrophic cardiomyopathy, congestive heart failure, cerebrovascular accident, hepatotoxicity, and serious psychiatric manifestations, including major depression, mania, paranoia, psychosis, delusions, hallucinations, hostility and aggression.

The following adverse reactions have also been reported in men: transient ischemic attacks, convulsions, hypomania, irritability, dyslipidemias, testicular atrophy, subfertility, and infertility. The following additional adverse reactions have been reported in women: hirsutism, virilization, deepening of voice, clitoral enlargement, breast atrophy, male-pattern baldness, and menstrual irregularities.

The following adverse reactions have been reported in male and female adolescents: premature closure of bony epiphyses with termination of growth, and precocious puberty. Because these reactions are reported voluntarily from a population of uncertain size and may include abuse of other agents, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
BACKGROUND: Facial feminization surgery (FFS) is an emerging practice that falls under the broader umbrella of gender-affirming surgery. Various approaches exist to feminize the face, yet few published articles describe in detail the techniques of each component procedure. Considering the diversity of interventions employed, the objective of this manuscript is to highlight FFS techniques utilized by the senior author and create a corresponding media gallery.
METHODS: All patients with the diagnosis of gender dysphoria that were referred to the senior author for FFS consultation between June 2017 and August 2022 were reviewed. Data were retrospectively collected from electronic medical records according to the institutional review board (IRB)-approved study protocol. Data collected and analyzed included demographics, operative documentation, and postoperative follow-up. Multimedia material was collected intraoperatively and postoperatively.
RESULTS: A total of 231 patients underwent 262 operations with a total of 1224 FFS procedures. The average follow-up time was 7.7 ± 11 months. Out of the 262 operations, 24 (9.2%) patients experienced minor complications, including 3 (1.1%) with wound dehiscence, 13 (5.0%) with hematomas, and 14 (5.3%) with postoperative infection requiring antibiotics. Of those, 3 (1.1%) required a return to the operating room for washout or removal of malar implants.
CONCLUSION: Although there is a consensus on the fundamental surgical principles to achieve adequate feminization of the facial architecture, the specific techniques to do so differ according to individual practices. As techniques diverge, so do their risk profiles and outcomes; techniques must, thus, align with patients' interventional goals. The material presented here is one of many that can support trainees and junior surgeons as they build a gender-affirming practice.
In arm 2, the child will use the conventional measures described above in addition to a digital behind-the-ear hearing aid with a standard ear hook and custom ear mold on the affected ear. The hearing instrument will be customized by an audiologist. The subject will be instructed to wear the hearing aid both at home and at school. In both arms, the FM system will be used in school only. As in the first arm, the HEAR-QL, CHILD (child) questionnaire, and LIFE-R student questionnaire will be administered to the child at the beginning, midpoint, and conclusion of this 3-month arm. The CHILD (parent) questionnaire will be administered to the parent and the LIFE-R teacher questionnaire will be administered to the teacher at the same intervals. No washout period will take place between the two arms. Subjects will be randomized to complete one arm first for 3 months, followed immediately by 3 months in the opposite arm.
The experimental group will undergo profound neuropsychological and psychological assessment before starting the integrative neurocognitive remediation therapy, in addition to the assessment already done at baseline. This group will repeat the testing after completion of the integrative neurocognitive remediation therapy, and 6 months thereafter.
AIMS: Hypertrophic cardiomyopathy (HCM) is an autosomal dominant genetic cardiac disorder characterized by unexplained left ventricular hypertrophy. It can cause a wide spectrum of clinical manifestations, ranging from asymptomatic to heart failure and sudden cardiac death (SCD). Approximately half of HCM cases are caused by variants in sarcomeric proteins, including α-tropomyosin (TPM1). In this study, we aimed to characterize the clinical and molecular phenotype of HCM in an Iranian pedigree with SCD.
METHODS AND RESULTS: The proband and available family members underwent comprehensive clinical evaluations, including echocardiography, cardiac magnetic resonance (CMR) imaging and electrocardiography (ECG). Whole-exome sequencing (WES) was performed in all available family members to identify the causal variant, which was validated, and segregation analysis was conducted via Sanger sequencing. WES identified a novel missense variant, c.761A>G:p.D254G (NM_001018005.2), in the TPM1 gene, in the proband, his father and one of his sisters. Bioinformatic analysis predicted it to be likely pathogenic. Clinical features in affected individuals were consistent with HCM.
CONCLUSIONS: The identification of a novel TPM1 variant in a family with HCM and SCD underscores the critical role of genetic screening in at-risk families. Early detection of pathogenic variants can facilitate timely intervention and management, potentially reducing the risk of SCD in individuals with HCM.
Myelosuppression, including pancytopenia, leukopenia, and anemia, some with fatal outcomes, have occurred with TEMODAR [see Adverse Reactions (6.1, 6.2)].

In MK-7365-006, myelosuppression usually occurred during the first few cycles of therapy and was generally not cumulative. The median nadirs occurred at 26 days for platelets (range: 21 to 40 days) and 28 days for neutrophils (range: 1 to 44 days). Approximately 10% of patients required hospitalization, blood transfusion, or discontinuation of therapy due to myelosuppression. Geriatric patients and women have been shown in clinical trials to have a higher risk of developing myelosuppression.

Obtain a complete blood count and monitor ANC and platelet counts before initiation of treatment and as clinically indicated during treatment. When TEMODAR is used in combination with radiotherapy, obtain a complete blood count prior to initiation of treatment, weekly during treatment, and as clinically indicated [see Dosage and Administration (2.1, 2.2, 2.3)].

For severe myelosuppression, withhold TEMODAR and then resume at same or reduced dose, or permanently discontinue, based on occurrence [see Dosage and Administration (2.1, 2.2, 2.3)].
<P>PROBLEM TO BE SOLVED: To provide an external plaster whose adhesive layer has improved solubility for estradiol and/or its derivative contained in the adhesive layer as an active ingredient, in whose support the active ingredient is not adsorbed, and which itself can follow the uneven surface or movement of skin.  <P>SOLUTION: This estradiol-containing plaster comprising the support and the adhesive layer is characterized by preparing the adhesive layer from an acrylic adhesive containing 0.01 to 1 wt. % of an isocyanate-based cross-linking agent as an essential component, and containing the estradiol and/or its derivative as the active ingredient, 0.1 to 10 wt. % of crotamine and 0.1 to 10 wt. % of oleic acid.  <P>COPYRIGHT: (C)2004,JPO
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely rehabilitation medicine, physiotherapy and urology and may be used for the purpose of rehabilitation of the patients suffering urolithiasis following lithitripsy. That is ensured by the intake of the herbal tea "Veres" containing wild camomile blossom, knotgrass herb, nosebleed herb and horsetail herb, juniper fruits, sage leaves, birch leaves, red bilberry leaves, linseeds taken in equal proportions. The infusion is taken in a dose of 100 ml 3 times a day 30 minutes before meals for 5-7 preoperative days. The common background therapy follows the lithotripsy procedure. That is combined with the additional intake of the herbal tea "Veres" for 10 days following the above procedure and hydrocarbonate sulphate calcium-magnesium mineral water "Kazachinskaya" of mineralisation 1.44g/l for 24 days following lithotripsy. The mineral water "Kazachinskaya" is taken in a dose of 200-250 ml 3 times a day before meals. Further, after the lithotripsy procedure, a projection of the involved kidneys and renal duct is exposed to the apparatus Bemer-3000 at AC field frequency 30-1000 Hz and magnetic field intensity 8.5-100 mcT. The exposure is generated by an intensive contact applicator from 2 fields in the mode-1 (2-4 stages) of 8 minutes. The therapeutic course makes 10 daily procedures. The background therapy is followed by another one-month intake of the herbal tea "Veres", as well as by another exposure to the apparatus "Bemer-3000" at the same parameters of the electromagnetic field. The contact exposure also covers the kidneys and the lower one-third of the renal duct by means of the intensive application from 2-4 fields in the mode-2 (2-4 stages) of 12 minutes. The exposure is daily, two times a day.EFFECT: method provides reducing the length of calculus fragments discharge following the lithotripsy procedure, improving the clinical and biochemical blood and urine statuses, renal blood flow, treating and preventing the postoperative complications, recovering the immunological responsiveness and antioxidant protection.4 dwg, 3 tbl, 2 ex
Part 3 will be a randomized Phase II study in which subjects will be administered the RCR as previously identified. Part 3 will be initiated only if an RCR is identified, and sufficient anticancer activity is observed in Parts 1 and 2.
PURPOSE: Intraflagellar transport 46 (IFT46) is an integral subunit of the IFT-B complex, playing a key role in the assembly and maintenance of primary cilia responsible for transducing signaling pathways. Despite its predominant expression in the basal body of cilia, the precise role of Ift46 in ocular development remains undetermined. This study aimed to elucidate the impact of neural crest (NC)-specific deletion of Ift46 on ocular development.
METHODS: NC-specific conditional knockout mice for Ift46 (NC-Ift46F/F) were generated by crossing Ift46F mice with Wnt1-Cre2 mice, enabling the specific deletion of Ift46 in NC-derived cells (NCCs). Sonic Hedgehog (Shh) and Notch signaling activities in NC-Ift46F/F mice were evaluated using Gli1lacZ and CBF:H2B-Venus reporter mice, respectively. Cell fate mapping was conducted using ROSAmTmG reporter mice.
RESULTS: The deletion of Ift46 in NCCs resulted in a spectrum of ocular abnormalities, including thickened corneal stroma, hypoplasia of the anterior chamber, irregular iris morphology, and corneal neovascularization. Notably, this deletion led to reduced Shh signal activity in the periocular mesenchyme, sustained expression of key transcription factors Foxc1, Foxc2 and Pitx2, along with persistent cell proliferation. Additionally, it induced increased Notch signaling activity and the development of ectopic neovascularization within the corneal stroma.
CONCLUSIONS: The absence of primary cilia due to Ift46 deficiency in NCCs is associated with anterior segment dysgenesis (ASD) and corneal neovascularization, suggesting a potential link to Axenfeld-Rieger syndrome, a disorder characterized by ASD. This underscores the pivotal role of primary cilia in ensuring proper anterior segment development and maintaining an avascular cornea.
Subjects will get either whole brain radiation treatment (WBRT) or stereotactic radiosurgery (SRS), as per standard of care, with tremelimumab administered every 28 days. Patients, for whom concurrent HER2 directed therapy trastuzumab is indicated, as determined by the treating investigator, will be enrolled in a parallel HER2 directed therapy trastuzumab safety cohort. Protocol Expansion: Dose 1 of tremelimumab \& durvalumab (75 mg \& 1500 mg, respectively) will ideally be administered 2 days prior to initiation of brain radiotherapy (or between 5 days prior \& 3 days after initiation of radiotherapy). Subjects will get either WBRT or SRS, depending on the number \& size of their brain metastases. Following the 1st dose, tremelimumab \& duvralumab will be administered q28 days from the date of 1st tremelimumab \& durvalumab administration, plus or minus 1 week, for 4 cycles. After the 4th cycle, durvalumab will be administered alone until progression of disease or unacceptable toxicity.
A phase change particulate saline slurry and methods and apparatus are provided for producing phase change particulate saline slurries. One method for producing phase change particulate saline slurries includes the steps of providing a liquid with a set percentage freezing point depressant, such as, a set percentage saline solution; subcooling the saline solution to a freezing point to produce ice particles; and increasing an ice particle concentration under controlled temperature for a period of time to provide a set ice particle concentration for the phase change particulate saline slurry. In another method for producing phase change particulate saline slurries, water and a first set amount of sodium chloride are provided to produce a saline solution. The saline solution is cooled to a set temperature. A selected percentage of chunk ice is added to the saline solution and the chunk ice is broken into ice particles. The ice particles have a small size. Next a second set amount of sodium chloride is added and distributed for smoothing of the ice particles. The total saline solution concentrations resulting from the total of the first set amount and the second set amount of added sodium chloride are preferably in the range of about 0.5% to 6.0%. The loadings or percentage of ice particles are preferably in the range of 5% to 50%. A phase change particulate saline slurry includes a water and sodium chloride solution. The sodium chloride is provided in a range between about 0.5% to 6.0%. A percentage of ice particles is provided in the range between about 5% to 50%. The ice particles have a size of about 1 mm or less than 1 mm; and the ice particles have a generally smooth shape.